Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature

Wnt-activated medulloblastoma (MB) confers an excellent prognosis. However, specific treatment strategies for patients with relapsed Wnt-MB are unknown. We report two patients with recurrent beta-catenin nucleopositive Wnt-MB successfully treated by incorporating marrow-ablative chemotherapy and aut...

Full description

Saved in:
Bibliographic Details
Published in:Child's nervous system 2022-02, Vol.38 (2), p.465-472
Main Authors: Harris, Micah K., Shatara, Margaret, Funk, Zachary, Stanek, Joseph, Boué, Daniel R., Jones, Jeremy, Finlay, Jonathan L., Abdelbaki, Mohamed S.
Format: Article
Language:English
Subjects:
Case Report
Medicine
Medicine & Public Health
Neurosciences
Neurosurgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Wnt-activated medulloblastoma (MB) confers an excellent prognosis. However, specific treatment strategies for patients with relapsed Wnt-MB are unknown. We report two patients with recurrent beta-catenin nucleopositive Wnt-MB successfully treated by incorporating marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue (HDCx/AuHPCR). We also present a review of the literature for previously reported cases of relapsed Wnt-MB. We propose that patients with recurrent Wnt-MB may be treated using a multi-disciplinary approach that includes HDCx/AuHPCR with or without re-irradiation.
ISSN:0256-7040
1433-0350
DOI:10.1007/s00381-021-05197-6